Physician profile
Peter E Jensen
NPI 1285602581
$512.64
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $60.16 · 2021: $249 · 2022: $59.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $184.28 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.83 | 2019-2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Sight Sciences, INC. | $36.08 | 2021-2022 | |
| Optovue, INC. | $34.59 | 2019 | |
| Merz Pharmaceuticals, LLC | $33.70 | 2021 | |
| Glaukos Corporation | $26.74 | 2021 | |
| Iridex Corporation | $24.73 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.58 | 2021 | |
| Ivantis, INC | $21.91 | 2019 | |
| Kala Pharmaceuticals, INC. | $20.24 | 2021 | |
| Allergan, INC. | $14.03 | 2021 | |
| Aerie Pharmaceuticals, INC. | $11.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.